Figure 1. Effect of 45 Days of Fondaparinux on Thromboembolism Risk After SVT
Some patients had more than one event. Death: fondaparinux, n = 2 (cancer); placebo, n = 1 (acute heart failure).
DVT, deep vein thrombosis; PE, pulmonary embolism; RRR, relative risk reduction; SFJ, saphenous-femoral junction; SVT, superficial vein thrombosis.
Source: Décousus H et al. N Engl J Med. 2010.
Reproduced with permission from H Décousus, MD.